EVM
ALNY icon

Eaton Vance Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Eaton Vance Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$61.5M Buy
307,288
+537
+0.2% +$102K 0.09% 219
2022
Q2 		$44.7M Buy
306,751
+523
+0.2% +$74.2K 0.06% 288
2022
Q1 		$50M Buy
306,228
+262,893
+607% +$40.1M 0.06% 306
2021
Q4 		$7.35M Sell
43,335
-674
-2% -$125K 0.01% 688
2021
Q3 		$8.29M Buy
44,009
+2,518
+6% +$472K 0.01% 602
2021
Q2 		$7.03M Sell
41,491
-4,378
-10% -$641K 0.01% 685
2021
Q1 		$6.48M Sell
45,869
-103,799
-69% -$15.6M 0.01% 671
2020
Q4 		$19.5M Sell
149,668
-64,315
-30% -$8.59M 0.03% 423
2020
Q3 		$31.2M Sell
213,983
-6,743
-3% -$958K 0.06% 286
2020
Q2 		$32.7M Buy
220,726
+112
+0.1% +$15.1K 0.07% 254
2020
Q1 		$24M Buy
220,614
+34
+0% +$3.92K 0.06% 269
2019
Q4 		$25.4M Sell
220,580
-24
-0% -$2.39K 0.05% 289
2019
Q3 		$17.7M Hold
220,604
– – 0.04% 338
2019
Q2 		$16M Sell
220,604
-131,129
-37% -$10.1M 0.04% 345
2019
Q1 		$32.9M Buy
351,733
+313,942
+831% +$26.3M 0.08% 238
2018
Q4 		$2.75M Hold
37,791
– – 0.01% 637
2018
Q3 		$3.31M Hold
37,791
– – 0.01% 632
2018
Q2 		$3.72M Buy
37,791
+975
+3% +$96.7K 0.01% 584
2018
Q1 		$4.38M Sell
36,816
-50
-0.1% -$6.45K 0.01% 527
2017
Q4 		$4.68M Buy
36,866
+5,000
+16% +$628K 0.01% 533
2017
Q3 		$3.74M Sell
31,866
-83
-0.3% -$7.08K 0.01% 552
2017
Q2 		$2.55M Hold
31,949
– – 0.01% 621
2017
Q1 		$1.64M Sell
31,949
-100
-0.3% -$4.62K ﹤0.01% 679
2016
Q4 		$1.2M Buy
32,049
+50
+0.2% +$2.09K ﹤0.01% 694
2016
Q3 		$2.17M Hold
31,999
– – 0.01% 571
2016
Q2 		$1.78M Sell
31,999
-100
-0.3% -$6.3K 0.01% 582
2016
Q1 		$2.02M Buy
32,099
+200
+0.6% +$13.3K 0.01% 550
2015
Q4 		$3M Sell
31,899
-100
-0.3% -$9.27K 0.01% 489
2015
Q3 		$2.57M Hold
31,999
– – 0.01% 505
2015
Q2 		$3.84M Buy
31,999
+21,600
+208% +$2.58M 0.01% 436
2015
Q1 		$1.09M Buy
10,399
+75
+0.7% +$7.6K ﹤0.01% 665
2014
Q4 		$1M Buy
+10,324
New +$956K ﹤0.01% 660

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Eaton Vance Management's ALNY Position: Q3 2022 in Review

Eaton Vance Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.18% in Q3 2022, buying an estimated $102K and bringing the position to 307,288 shares worth $61.5M. The position accounts for 0.09% of the portfolio, ranked #219.

Eaton Vance Management first reported a position in ALNY in Q4 2014 and has held it in 32 quarters since. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Eaton Vance Management held 307,288 shares of Alnylam Pharmaceuticals worth $61.5M as of Q3 2022.
  • Eaton Vance Management bought 537 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $102K.
  • Alnylam Pharmaceuticals made up 0.09% of Eaton Vance Management's portfolio in Q3 2022, its #219 holding.
  • Eaton Vance Management first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 32 quarters since.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.